SCHEMBL14923786

SCHEMBL14923786

N#Cc1cc(N)cnc1N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
KDM4E B2RXH2 4/20 0.51
HPGD P15428 3/20 0.51
RXFP1 Q9HBX9 2/20 0.51
HSD17B10 Q99714 2/20 0.51
GAA P10253 2/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
IKBKB O14920 1/20 0.47
CTSK P43235 2/20 0.47
POLB P06746 1/20 0.46
KMT2A Q03164 1/20 0.46
PIK3CA P42336 1/20 0.45
CLK1 P49759 1/20 0.45
MAPK1 P28482 2/20 0.44
TSHR P16473 1/20 0.44
KHK P50053 1/20 0.43
LRRK2 Q5S007 2/20 0.43
OPRM1 P35372 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30852546 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDRXFP1HSD17B10
SCHEMBL23168043 0.86 CNR2 (0.50) ALDH1A1KDM4EHPGDRXFP1HSD17B10
SCHEMBL30152422 0.86 CNR2 (0.50) ALDH1A1KDM4EHPGDRXFP1HSD17B10
SCHEMBL22279004 0.84 CNR2 (0.52) ALDH1A1KDM4EHPGDRXFP1HSD17B10
SCHEMBL17591637 0.84 RAF1 (0.53) ALDH1A1KDM4EHPGDRXFP1HSD17B10
SCHEMBL30852648 0.82 KDM4E (0.49) ALDH1A1KDM4EHPGDRXFP1CASP1
SCHEMBL22561873 0.82 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDRXFP1HSD17B10
SCHEMBL30206264 0.82 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDRXFP1HSD17B10
SCHEMBL19997592 0.82 KMT2A (0.52) ALDH1A1KDM4EHPGDRXFP1HSD17B10
SCHEMBL3353595 0.82 ALDH1A1 (0.51) ALDH1A1KDM4EHPGDRXFP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-05-07 US disclosed
WO-2024059559-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
WO-2020151686-A1 N-HETEROARYL SULFONAMIDE DERIVATIVE, PREPARATION AND USE THEREOF IN TREATMENT OF AUTOIMMUNE DISEASES 杭州壹瑞医药科技有限公司 2020-07-30 WO disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL6B ALDH1A1 1842/4885KDM4E 2254/4885HPGD 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.